Attenuating emerging contaminants - prospects and new approaches (CROSBI ID 715642)
Neobjavljeno sudjelovanje sa skupa | neobjavljeni prilog sa skupa
Podaci o odgovornosti
Vrček, Valerije
engleski
Attenuating emerging contaminants - prospects and new approaches
PPCPs selected (Table 1) for attenuation study are derived from the lists included in deliverables D.T1.3.1 (National review papers on emerging contaminants appearing in the water environment) and D.T3.3.3 (First set-up for modeling transport of emerging contaminants in hydrological systems). In these deliverables, all PPCPs were introduced by the authors (i.e. the members of the bo-DEREC- CE project), responsible for different pilot actions areas. In addition, PPCP with the highest concentration (in ng/L) measured in at each respective pilot action areas have also been included in Table 1 (if not present earlier in deliverables D.T1.3.1 and D.T3.3.3). This collection of PPCPs is broad and representative, as it containing contains ubiquitous compounds (carbamazepine, diclofenac), popular over-the- counter (OTC) drugs (ibuprofen), different therapeutic classes, such as antibiotics (sulfamethoxazole), hormones (progesterone, testosterone), antidiabetics (metformin), antihypertensives (valsartan), or anticonvulsants (lamotrigine, gabapentin), but also PPCP metabolites (oxypurinol, 4-formylaminoantipyrine) and personal care substances (DEET, benzotriazole). In addition, some of PPCPs listed in Table 1 (diclofenac, sulfamethoxazole) have been filed in the Watch List under the Water Framework Directive.
pharmaceuticals, environment
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o prilogu
nije evidentirano
nije evidentirano
Podaci o skupu
boDEREC-CE Final Conference
predavanje
02.03.2022-02.03.2022
Prag, Češka Republika